Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors
January 05, 2022 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
Outside research shows that in models of colorectal, triple-negative breast and pancreatic cancer, LB-100 induces molecular changes that render the cancers more vulnerable to immunotherapy ...
Embolization Agents Market Size ($4,525.75Mn by 2028) Lead by Coil Segment (7.6% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
October 22, 2021 08:22 ET
|
The Insight Partners
New York, Oct. 22, 2021 (GLOBE NEWSWIRE) -- The new research study on the Embolization Agents Market Size and Forecast to 2028 by Product (Coils, Plugs, Beads/Particles, Detachable Balloons, Glue,...
Eckert & Ziegler’s GalliaPharm® distributed by Curium in France
March 01, 2021 19:15 ET
|
Curium
Berlin, Germany and Paris, France, March 01, 2021 (GLOBE NEWSWIRE) -- Eckert & Ziegler Radiopharma GmbH and Curium PET France have decided to reinforce their existing long term partnership by...
Vivos Inc Extends it Intellectual Property Protection
December 01, 2020 09:30 ET
|
Vivos Inc.
Richland WA, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it received the Patent Cooperation Treaty (PCT) International Search Report on our patent...
RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.
September 08, 2020 13:52 ET
|
Curium
Houston, TX and St. Louis, MO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that DetectnetTM (copper Cu 64 dotatate injection) was approved by...
Hebrew University to Collaborate with Cytovia Therapeutics
March 18, 2020 09:00 ET
|
Cytovia Therapeutics
NEW YORK and JERUSALEM, March 18, 2020 (GLOBE NEWSWIRE) -- Yissum, the technology transfer company of The Hebrew University of Jerusalem and Cytovia Therapeutics, Inc, a biopharmaceutical company...
US FDA GRANTS PV-10 ORPHAN DRUG DESIGNATION FOR NEUROBLASTOMA
November 05, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company was granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA)...
PROVECTUS ANNOUNCES PRESENTATION OF PHASE 1 TRIAL OF PV-10 FOR TREATMENT OF SYMPTOMATIC NEUROENDOCRINE TUMORS METASTATIC TO LIVER AT ESMO 2018 CONGRESS
October 23, 2018 09:00 ET
|
Provectus Biopharmaceuticals Inc.
- First cohort of 6 patients enrolled and treated; currently recruiting patients into second cohort KNOXVILLE, TN, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that...
Embolization Coil reduced risks and cost-effectiveness, to witness a CAGR of 4.7% during 2017-2023
November 07, 2017 08:56 ET
|
Energias Market Research
NEW YORK, Nov. 07, 2017 (GLOBE NEWSWIRE) -- The global embolization coil market is expected to witness a CAGR of 4.7%, and is projected to reach USD 1,003.7 Million by 2023. Factors propelling the...
Elsevier Publishes Neural Data Science: A Primer with MATLAB(R) and Python(TM)
March 29, 2017 04:00 ET
|
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - March 29, 2017) - Elsevier, the information analytics company specializing in science and health, today announced the publication of Neural Data Science: A Primer with...